GlassScriptPhysician profile
Ibrahim Sayed-Ahmed
NPI 1487158556
$9,053.89
in general payments reported to CMS, 2019-2025
18 companies · $1,651 in 2025
The $1,651 reported for 2025 was more than what 86% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $190 · 2022: $415 · 2023: $950 · 2024: $5,848 · 2025: $1,651.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,770 · Travel and Lodging: $2,160 · Consulting Fee: $1,519.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,769.87 |
| Travel and Lodging | $2,159.96 |
| Consulting Fee | $1,519.23 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biotissue Holdings INC. | $5,089.49 | 2022-2025 | |
| Alcon Vision LLC | $1,784.10 | 2022-2025 | Clareon, Clareon Panoptix Pro, Hydrus Microstent |
| Abbvie INC. | $430.91 | 2024-2025 | |
| Glaukos Corporation | $408.16 | 2022-2025 | Is3-Istent Infinitetrabecular Micro-Bypass System Model Is3, Istent Infinite Trabecular Micro-Bypass System Model Is3, Ce-Marked Kxla System |
| Carl Zeiss Meditec USA, INC. | $200.06 | 2024 | Lumera 700, Iolmaster 700 |
| New World Medical,INC. | $189.65 | 2019 | |
| Harrow Eye, LLC | $174.09 | 2024 | |
| Mallinckrodt Hospital Products INC. | $173.77 | 2022-2025 | Acthar |
| Bausch & Lomb Americas INC. | $168.42 | 2023-2025 | Stellaris, Vyzulta, Miebo |
| Astellas Pharma US INC | $110.39 | 2024-2025 | Izervay |
| Genentech USA, INC. | $85.18 | 2025 | Vabysmo |
| Johnson & Johnson Surgical Vision, INC. | $72.38 | 2024 | Tecnis Iol, Tecnis Iol, Catalys System |
| Dompe US, INC. | $50.60 | 2023-2025 | Oxervate |
| Tarsus Pharmaceuticals, INC. | $27.31 | 2025 | Xdemvy |
| Apellis Pharmaceuticals, INC. | $24.09 | 2025 | Syfovre |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ani Pharmaceuticals, INC. | $23.85 | 2025 | Iluvien |
| Amgen INC. | $23.83 | 2025 | Tepezza |
| Sun Pharmaceutical Industries INC. | $17.61 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ibrahim Sayed-Ahmed listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.